Phase 2, 'Proof of Principle', Placebo Controlled, Randomised, Parallel Group Pilot Study of the Effect of a New Combined Acne Treatment in Patients with Mild to Moderate Acne.
Phase 2
Completed
- Conditions
- Mild to Moderate Acne vulgarisSkin - Dermatological conditions
- Registration Number
- ACTRN12607000140459
- Lead Sponsor
- ifeSource Group Holdings Pty Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Subjects with mild to moderate inflammatory acne; of any racial/ethnic group.
Exclusion Criteria
Oral retinoid use within 2 years of entry into the study; Systemic acne therapies within 4 weeks of entry into the study; Subjects with predominantly comedonal acne; Subjects with predominant retention acne.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Two grade improvement in Investigators Global Assessment (IGA) [Determined at 0, 4, 8 and 12 weeks.]
- Secondary Outcome Measures
Name Time Method Reduction in Inflammatory Lesion Count[Determined at 0, 4, 8 and 12 weeks.]